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The transfection ability of nonviral gene therapy ve-
hicles is generally hampered by untimely lysosomal deg-
radation of internalized DNA. In this study we describe
the development of a targeted lysosome disruptive ele-
ment to facilitate the escape of DNA from the lysosomal
compartment, thus enhancing the transfection efficacy,
in a cell-specific fashion. Two peptides (INF7 and JTS-1)
were tested for their capacity to disrupt liposomes. In
contrast to JTS-1, INF7 induced rapid cholesterol-inde-
pendent leakage (EC50, 1.3 M). INF7 was therefore se-
lected for coupling to a high affinity ligand for the asia-
loglycoprotein receptor (ASGPr), K(GalNAc)2, to im-
prove its uptake by parenchymal liver cells. Although
the parent peptide disrupted both cholesterol-rich and
-poor liposomes, the conjugate, INF7-K(GalNAc)2, only
induced leakage of cholesterol-poor liposomes. Given
that endosomal membranes of eukaryotic cells contain
<5% cholesterol, this implies that the conjugate will dis-
play a higher selectivity toward endosomal membranes.
Although both INF7 and INF7-K(GalNAc)2 were found to
increase the transfection efficiency on polyplex-medi-
ated gene transfer to parenchymal liver cells by 30-fold,
only INF7-K(GalNAc)2 appeared to do so in an ASGPr-
specific manner. In mice, INF7-K(GalNAc)2 was specifi-
cally targeted to the liver, whereas INF7 was distributed
evenly over various organs. In summary, we have pre-
pared a nontoxic cell-specific lysosome disruptive ele-
ment that improves gene delivery to parenchymal liver
cells via the ASGPr. Its high cell specificity and prefer-
ence to lyse intracellular membranes make this conju-
gate a promising lead in hepatocyte-specific drug/gene
delivery protocols.
The development of a viable nonviral gene delivery system
continues to be an important theme in gene therapy (1). The
packaging of DNA into compact particles, the cellular uptake,
the endosomal escape, and unpacking of these particles as well
as the subsequent transfer of DNA to the nucleus are consid-
ered important steps in this regard (2). A number of DNA-
packaging compounds have been reported, including cationic
lipids, polymers and/or peptides that were designed to self-
assemble with DNA to form intermolecular complexes (3–8).
Upon internalization, the packaged DNA is transported to the
lysosome, which subsequently degrades its content, making
lysosomal escape a key step in gene delivery. To facilitate the
intracellular transport of the packaged DNA to the nucleus and
thus to enhance the transfection capacity of the nonviral gene
delivery vehicles, lysosome disruptive elements (LDEs)1 have
been successfully applied, including amphipathic peptides
(9–16).
The majority of the amphipathic peptides are derived from
viral elements that promote cellular entry and correct intracel-
lular handling. Their membrane permeabilizing capacity gen-
erally depends on the lipid composition and the pH. Although
they are random coil at pH 7.0, these peptides undergo a
conformational change into an amphipathic -helix at pH 5.0
and aggregate into multimeric clusters (11, 12). Subsequently,
the clustered helical peptides associate with and/or penetrate
endosomal membranes, thereby destabilizing the membrane.
Apart from complete virus capsids and purified capsid proteins,
hemagglutinin (HA)-derived peptides and synthetic analogs
have also been shown to induce pH-sensitive membrane dis-
ruption, leading to improved transfection of DNA-polycation
complexes in vitro (9, 17). Although several groups have stud-
ied the stimulatory effect of LDEs on nonviral gene transfer
(18–20), the use of targeted LDEs, which concomitantly im-
prove the cellular delivery of DNA and its translocation to the
nucleus, is rather unexplored.
Previous studies have shown that coupling of a homing de-
vice to liposomes or a universal carrier leads to a higher uptake
of liposome-encapsulated drugs by the target cell (6, 23–25).
The same strategy was applied to generate a targeted LDE.
Two fusogenic peptides, INF7, a 23-mer peptide from HA, and
JTS-1, an artificial INF7 mimic designed for pH-sensitive helix
formation, were studied (10, 21, 22). INF7, the most promising
peptide in terms of cholesterol dependence and disruption ki-
netics, was equipped with a homing device for the asialoglyco-
protein receptor (ASGPr), K(GalNAc)2 (1, 9, 23–26) on paren-
chymal liver cells.
In this report, we show that the glycoconjugated peptide,
INF7-K(GalNAc)2, displays a high affinity for the ASGPr and
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possesses high lytic activity in cholesterol-poor liposomes only,
making it eminently suitable for targeted fusogenic activity in
parenchymal cells. Moreover, INF7-K(GalNAc)2, unlike the pa-
rental INF7, accumulates efficiently in the liver after in vivo
administration and strongly improves the transfer of poly-
plexed genes to parenchymal liver cells in an ASGPr-dependent
fashion.
EXPERIMENTAL PROCEDURES
Materials—Egg yolk phosphatidylcholine was purchased from Fluka
(Buchs, Switzerland). Cholesterol (99%), calcein, trypsin inhibitor
(bovine origin), orosomucoid, Triton X-100, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT), and BSA were obtained from
Sigma. Precipath L was from Roche Molecular Biochemicals. Sepharose
G50 and G10 were from Amersham Biosciences. Agarose was from
Eurogentec (Seraing, Belgium), and dimethyl sulfoxide was obtained
from Baker. All solvents were of analytical grade. Dry solvents were
stored over molecular sieves of 4 Å. Kieselgel 60 F254 plates were from
Merck. Polyethylene glycol-PS resin was purchased from PerkinElmer
Life Sciences. Fmoc amino acids were purchased from Nova Biochem
(Bad Soden, Germany). K(GalNAc)2 was synthesized as described by
Valentijn et al. (26). KWKKK KKKKK AKY (K8) was kindly provided
by A. van Keulen (Leiden University, Leiden, The Netherlands).
Analysis—For TLC analysis, compounds were visualized by charring
with sulfuric acid/ethanol (1/4, v/v) or with a 0.3% solution of ninhy-
drine in acetic acid/1-butanol (3/100, v/v). Column chromatography was
performed with Kieselgel 60, 230–400 mesh (Merck). 1H NMR spectra
(300 MHz) were recorded with a Bruker WM-300 spectrometer. Solid
phase synthesis was performed on an ABI 433 peptide synthesizer.
Products were analyzed with a Jasco HPLC system using a LiChro-
spher 100 RP-18 column (Merck, 5 m, 4.6  250 mm). Automated
purification was performed using BIOCAD VISION. Electrospray mass
spectra were recorded with a PerkinElmer SCIEX API 165 single qua-
drupole LC-MS instrument. Matrix-assisted laser desorption/ionization
(MALDI) time-of-flight (TOF) mass spectrometry was performed on a
PerkinElmer/PerSeptive Biosystems Voyager-DE-RP MALDI-TOF
mass spectrometer.
Peptide Synthesis—JTS-1 (GLEEALLFLLESLWELLLEA) was a
generous gift from Dr. Tagliaferri (Valentis, Inc., Burlingame, CA).
INF-7 (GLFEAIEGFIENGWEGMIWDYG) was prepared by solid phase
synthesis on an ABI 433 peptide synthesizer (Wang resin, loading (L)
0.64 mmol/g) analogous to the procedure described by Planck et al. (19).
A 50-mol scale synthesis was performed using Fmoc/tertiary-butyl or
Fmoc/trityl-protected amino acids with a BOP/HOBt activation strat-
egy. Deprotection and cleavage of the peptide from the resin in a
solution of 95% trifluoroacetic acid, 2.5% H2O, and 2.5% triisopropylsi-
lane were followed by precipitation of the peptide in ether. The precip-
itated crude INF7 was analyzed by LC-MS using a reversed phase C18
column eluted with a CH3CN gradient (5–50% CH3CN) in ammonium
bicarbonate buffer (10 mM NH4HCO3) followed by HPLC purification
eluting with a 20–40% CH3CN gradient in aqueous 10 mM NH4HCO3.
The product fractions were combined, concentrated, and subsequently
lyophilized twice. The purity of the product (99%) was monitored by
analytical HPLC and analysis with MALDI-TOF spectrometry (molec-
ular weight: calculated, 2589.1; found, 2612.2 [MNa]). The spacer
arm containing INF7 (GLFEAIEGFIENGWEGMIWDYGSGSCG) was
prepared under essentially the same conditions. The cysteine-protected
peptide was synthesized and isolated as described above. Reversed
phase HPLC yielded a product of 95% purity as was assessed by
LC-MS (CH3CN gradient in 10 mM NH4Ac, molecular weight: 3012,
found weight, 1507; [M2H]2). The peptide was taken up in 40 mM
dithiothreitol in NH4HCO3 buffer) for a period of 1.5 h during which the
deprotection of the cysteine residue was monitored by LC-MS. The
peptide was purified (see above) (98%) and analyzed by LC-MS (molec-
ular weight: 2924; found, 1463 [M2H]2).
Preparation of the glycoconjugated INF7 peptide (Fig. 1, INF7-
K(GalNAc)2) commenced with the synthesis of a divalent lysine-based
cluster galactoside on commercially available polyethylene glycol-PS
resin, prior to introduction of the INF7 peptide. To this end, FmocLys-
(Boc)-OH was attached to commercially available polyethylene gly-
col-PS via a hydroxymethylbenzoic acid linker to obtain 1 (Scheme 1, L
0.19 mmol/g). Subsequently, the Boc group was removed from the lysine
side chain using trifluoroacetic acid in dichloromethane and the
-amine group coupled to BocLys(Boc)-OH in the presence of O-7-
azabenzotriazol-1-yl)-N,N,N,N-tetramethyluroniumhexafluorophos-
phate/n,n-di-isopropylethylamine (HATU/DiPEA). Deprotection of the
latter lysine residue with trifluoroacetic acid/dichloromethane resulted
in two free amine groups thus permitting simultaneous introduction of
both galactosamine-derived moieties 2 to give resin immobilized cluster
galactoside 3 (L 0.10 mmol/g) (Scheme 1) (26). The obtained resin was
treated with a 20% piperidine solution in N,N-dimethylformamide to
remove the Fmoc protecting group, and the resulting free -amino
group was elongated with the SGSC amino acid spacer, followed by
assembly of the INF-7 peptide as described above. Final deprotection
and cleavage from the resin of the glycoconjugated INF7 4 (Fig. 1) were
performed as follows. Removal of the acid-labile tBu and Trt side chain
protecting groups was achieved by treatment of the resin with triflu-
oroacetic acid, 2.5% H2O, 2.5% triisopropylsilane, and 2.5% ethanedi-
thiol (27), followed by washing with trifluoroacetic acid, 5% H2O (twice),
and H2O (three times). Cleavage of the INF7 derivative 4 (Fig. 1) from
the resin and simultaneous debenzoylation of the galactosamine moi-
eties were achieved by uptake of the resin in an aqueous 0.4 M NaOH
solution at 4 °C. The cysteine residue was deprotected using tribu-
tylphosphine in isopropyl alcohol. The obtained glycoconjugated peptide
was analyzed by analytical HPLC (CH3CN gradient in 10 mM
NH4HCO3) and LC-MS (CH3CN gradient in 10 mM NH4Ac) assessed the
presence of compound 4 (Fig. 1) as the main (95%) product. Further
purification by RP-HPLC using a CH3CN gradient (5–50% CH3CN) in
10 mM NH4HCO3 buffer gave conjugate 4 (Fig. 1) in an overall yield of
26% (99% pure). The product was analyzed by MALDI-TOF spectrom-
etry (molecular weight: 3787.3 [MH] and 3809.3 [MNa], calcu-
lated, 3786.5) and lyophilized.
Leakage Assay—Phosphatidylcholine/cholesterol vesicles containing
calcein were prepared by sonication. Briefly 100 mg/ml egg yolk phos-
phatidylcholine and cholesterol in methanol/chloroform (10 and 100
mg/ml) were dried under a stream of nitrogen. The lipid mixture was
resuspended in sonication buffer (375 mM NaOH, 50 mM NaCl, pH 7.4)
containing 100 mM calcein and sonicated with amplitude of 10 m for 15
min (2.6% cholesterol) to 20 min (40% cholesterol) at 54 °C with a probe
sonicator (Beun de Ronde, Abcoude, The Netherlands). Free calcein was
separated from liposome-entrapped calcein by using a Sephadex G-50
column. Liposome size was measured routinely by photon correlation
spectroscopy (Malvern Instruments, Malvern, UK) to exclude small and
large particles. Measurements were performed at 27 °C and at a 90-
degree angle. The average liposome size was 100 nm. The cholesterol
content of the purified calcein laden liposomes was determined using a
Roche enzymatic kit for cholesterol using Precipath L as a reference (28).
Calcein release was measured at 535 nm (ex  485 nm) using a
fluorescence spectrophotometer (PerkinElmer Life Sciences). For the
leakage assay the calcein-laden liposomes were diluted in citrate-buff-
ered saline (200 mM NaCl, 20 mM sodium citrate), pH 7.0 or pH 5.0, and
peptide was added at a concentration of 0–20 M. Fluorescence was
measured 0–60 min after the addition of the peptide. Complete lysis
was achieved by adding Triton X-100 to a final concentration of 0.25%.
Leakage of Liposome-entrapped Trypsin Inhibitor—Liposomes were
loaded with 125I-trypsin inhibitor (molecular weight 20,000) as follows.
Trypsin inhibitor was radioiodinated according to McFarlane (29) to a
specific activity of 2340 dpm/ng (free 125I  5%). Liposomes were soni-
cated as described above in buffer (5 mM Hepes, 40 mM NaCl, pH 7.4)
containing 125I-trypsin inhibitor (33.8  106 dpm). Free 125I-trypsin
inhibitor was removed by density ultracentrifugation (40,000 rpm) for
FIG. 1. Synthetic structure of INF7-K(GalNAc)2.
SCHEME 1. i, trifluoroacetic acid/DCM; ii, BocLys(Boc)-OH/HATU/
DiPEA; iii, trifluoroacetic acid/DCM; iv, 2, BOP/HOBt/DiPEA.
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16–18 h at 4 °C (30). Particles were characterized by size and choles-
terol concentration.
For the leakage assay, the liposomes were diluted in citrate-buffered
saline, pH 7.0 or pH 5.0. Fusogenic peptide was added to a concentra-
tion of 0–20 M, and the amount of leakage was monitored by 0.75%
w/w agarose gel electrophoresis in Tris/hippuric acid buffer, pH 8.8.
Radioactivity was visualized using the PhophorImager (Molecular
Dynamics, Sunnyvale, CA).
Isolation of Mouse Parenchymal Liver Cells—10–12-week-old male
C57BL/6KH mice weighing 22–27 g (Broekman Institute BV, Someren,
The Netherlands) were used for parenchymal cell isolation. Hepato-
cytes were isolated from anesthetized mice by perfusion of the liver with
collagenase (type IV, 0.05% w/v) for 10 min at 37 °C according to the
method of Seglen (31). Cells were 99% pure as judged by light
microscopy.
In Vitro Binding Assay—Displacement of 125I-ASOR binding to
mouse hepatocytes was determined as follows (32). Freshly isolated
mouse parenchymal liver cells (1  106 cells, viability 90% as deter-
mined by 0.2% trypan blue exclusion) were incubated in 0.5 ml of
Dulbecco’s modified Eagle’s medium (Biowhittaker, Verviers, Belgium)
containing 2% BSA with 5.5 nM 125I-ASOR in the presence or absence of
50 nM-5 M displacer. After incubation for 2 h at 4 °C under gentle
agitation, the medium was removed by aspiration, and the cells were
washed twice with 0.2% BSA in medium and once with medium lacking
BSA. Subsequently cells were counted for radioactivity. Cell binding
was corrected for protein content. Nonspecific binding was measured in
the presence of 100 mM GalNAc. Displacement binding data were ana-
lyzed according to a single site model using a computerized nonlinear
fitting program (Prism) to calculate the Ki.
Transfection of Mouse Parenchymal Cells—The pCMV-luciferase,
containing the firefly luciferase cDNA insert, was kindly provided by
Crucell BV (Leiden, The Netherlands). The preparation of the K8DNA
polyplexes (N:P charge ratio 4:1; 1 g of DNA/well in HBS buffer) was
done as described by Gottschalk et al. (10). Mouse parenchymal liver
cells were transfected 3 h after seeding (2  105 cells/well) with K8-
condensed DNA. After a 30-min incubation of the K8DNA complexes at
room temperature, fusogenic peptides (INF7, INF7-SGSC, and INF7-
K(GalNAc)2) were added to a final concentration of 1–2,000 nM. After an
additional incubation of 30 min at room temperature, the complexes
were added directly to the parenchymal cells in 250 l of Dulbecco’s
modified Eagle’s medium  0.2% BSA. After incubating for 4 h, 1 ml of
medium was added, and the cells were incubated for 44 h. After har-
vesting of the cells the lysate was analyzed for luciferase activity as
described (33) and corrected for protein content (BCA) using BSA as
reference.
In analogy, BHK cells (seeded at 2  106 cells/well) were transfected
with preformed K8DNA condensates in the absence or presence of the
fusogenic peptides.
MTT Cytotoxicity Test—Parenchymal liver cells were transfected as
described above. After a 48-h incubation the medium was replaced by
fresh medium, and MTT was added to a final concentration of 0.5
mg/ml. Cells were incubated for 30 min at 37 °C, the medium was
removed, and dimethyl sulfoxide was added to the cells. Extinction was
measured at 550 nm.
Liver Uptake and Serum Decay of INF7 and INF7-K(GalNAc)2 in
Mice—Male C57BL/6KH mice (19–21 g) were anesthetized, and the
abdomens were opened. 125I-INF7 and 125I-INF7-K(GalNAc)2 were in-
jected via the inferior vena cava. At the indicated times blood samples
of 50 l were taken from the inferior vena cava and allowed to clot for
30 min. Serum samples of 10 l were counted for radioactivity after
centrifugation for 5 min at 2,500  g. To determine liver uptake, liver
lobules were tied off at the indicated times, excised, and weighed. At 30
min, mice were sacrificed, and organs were excised and weighed. Ra-
dioactivity in serum, liver, and other tissue samples was counted in a
gamma counter (minaxi -counter 5000, Packard) and corrected for
radioactivity in entrapped serum as described by Rensen et al. (28). The
weight of muscle, bone, and skin was calculated from the whole body
weight of the mouse and the average contribution of the organ to the
body weight by the formula: % tissue in standard mouse (muscle 
22.52%, bone  16.71%, skin  14.74%)/100  weight of mouse/weight
of tissue sample.
RESULTS
Lytic Activity of JTS-1 and INF7—To improve the intracel-
lular trafficking of nonviral DNA vehicles in a cell-specific
fashion, we wanted to target a LDE to the ASGPr on paren-
chymal liver cells. In the first step, we synthesized two fuso-
genic peptides with known lysosome disruptive activity, JTS-1
and INF7.
The membrane-disruptive properties of JTS-1 and INF7
were determined by a liposome leakage assay, in which the
release of calcein from phosphatidylcholine liposomes was
measured. Liposomes with various cholesterol contents were
prepared to address whether the lytic capacity of the peptides
depends on the cholesterol content of the membranes. Eukary-
otic plasma membranes generally contain between 20 and 25%
cholesterol, whereas the cholesterol content of endosomal mem-
branes ranges from 0 to 5% (34, 35). Cholesterol dependence is
therefore an important criterion in the development of a tar-
geted LDE because it should act specifically on endosomal
membranes, leaving cell membranes unaffected.
Leakage of INF7 and JTS-1 was monitored in time at pH 5.0
and pH 7.0. Both peptides appear to be disruptive at acidic pH
only (Fig. 2). In agreement with previous studies (10, 20), a
kinetic study of calcein release revealed that in cholesterol-rich
(40%) liposomes the INF7-induced leakage was much more
rapid than that of JTS-1 (t1/2  0.24 min versus 33.53 min,
respectively; p 0.001) (Fig. 3B). The kinetics of INF7-induced
leakage of cholesterol-poor (2.6%) liposomes was found to be
quite similar (t1/2  0.27 min, p  0.01), whereas that of JTS-1
was accelerated considerably compared with that of cholester-
ol-rich liposomes (t1/2  4.9 min) (Fig. 3C). Moreover JTS-1
induced partial leakage of liposomes containing 2.6% choles-
terol (Fig. 3C).
Further study confirmed the differential cholesterol depend-
ence of JTS-1- and INF7-induced lysis. Whereas INF7 was
equally fusogenic in liposomes with high and low cholesterol
content, JTS-1 was only able to disrupt cholesterol-rich lipo-
somes completely (Fig. 3A).
From these results we concluded that INF7 caused a rapid,
cholesterol-independent disruption with an EC50 of 1.3 M,
whereas JTS-1-induced leakage is much slower and cholesterol-
dependent. Given that the lysosomal membrane is cholesterol-
poor, we selected INF7 for subsequent design of a targeted
fusogenic peptide, by conjugation to the -K(GalNAc)2 ligand
(Fig. 1).
FIG. 2. Liposome leakage assay of
INF7 (A) and JTS-1 (B). Calcein-laden
2.6% cholesterol containing liposomes
were incubated at pH 7.0 (f) and pH 5.0
(Œ) with various concentrations of pep-
tide. Calcein release was quantified after
30 min of incubation as described under
“Experimental Procedures.” Data shown
are the means  S.D. of a triplicate
determination.
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In Vitro Binding Studies—The affinity of INF7-K(GalNAc)2
for the ASGPr was monitored by an in vitro competition assay
of 125I-ASOR total binding to mouse parenchymal liver cells. As
shown in Fig. 4, INF7-K(GalNAc)2 inhibited the binding of
ASOR to the ASGPr (Kd 87 nM), which is comparable with that
of K(GalNAc)2 (Kd 32 nM). We previously used the K(GalNAc)2
with comparable affinity (32, 41). This indicates that attach-
ment of the INF7 peptide to K(GalNAc)2 did not affect the
affinity of K(GalNAc)2 for the ASGPr considerably. To exclude
nonspecific binding caused by the presence of the SGSC linker
arm between the GalNAc cluster and the peptide, an INF7-
SGSC was synthesized and tested for the affinity of the ASGPr.
INF7 and INF7-SGSC, the peptide with the SGSC linker arm
between the peptide and GalNAc, did not show any affinity for
the ASGPr (Fig. 4), confirming the importance of K(GalNAc)2
in the binding to ASGPr.
Lytic Activity of INF7 and the INF7 Glycoconjugate—The
membrane-disruptive potency of INF7-K(GalNAc)2 was deter-
mined in the liposome leakage assay, similar to INF7 and
JTS-1. INF7-K(GalNAc)2 displayed only lytic activity at acidic
pH (data not shown). The leakage kinetics of INF7-K(GalNAc)2
were comparable with that of INF7 (Fig. 5). In cholesterol-poor
(2.6%) liposomes, the fusogenic capacity of the glycoconjugate
appeared to be five times lower than that of the parental INF7
(Fig. 5B) (EC50 1.3 and 6.1 M, respectively). A closer look at
the cholesterol dependence of liposome leakage showed that the
fusogenic activity of INF7-K(GalNAc)2 was impaired markedly
in liposomes with cholesterol contents above 20% (Fig. 5C).
When aiming at lysosome-specific membrane disruption, this is
a clear advantage because lysosomal membranes are known to
contain low cholesterol concentrations, whereas plasma mem-
branes are generally rich in cholesterol. This implies that
INF7-K(GalNAc)2 may be even more specific for lysosomal
membranes, while leaving the cell membrane intact.
Mechanism of Leakage—We argued that the differential
capacity of INF7 and INF7-K(GalNAc)2 to lyse cholesterol-rich
membranes might be related to the actual mechanism of mem-
brane disruption. Previous studies have shown that am-
phipathic peptides are disruptive either by facilitating pore
formation after multimeric assembly of the peptide or by in-
ducing a more detergent-like solubilization of the liposome
leading to complete disruption of the liposome. It was reasoned
that pore formation might restrict the leakage of entrapped
compounds with a low molecular weight, whereas the molecu-
lar weight of entrapped compounds would not be a limiting
factor after complete disruption of the liposomes (36). For that
reason we studied the size-dependent leakage of INF7 and
INF7-K(GalNAc)2 in liposomes containing either calcein (mo-
lecular weight, 622) or 125I-trypsin inhibitor (molecular weight,
20,000). Liposomes were incubated with INF7 or INF7-K(Gal-
NAc)2 (0–20 M). At pH 7.0, no leakage of calcein or trypsin was
observed for up to 60 min of incubation. However, under acidic
conditions, INF7 and INF7-K(GalNAc)2 promoted the release
of calcein but not of entrapped 125I-trypsin inhibitor (Fig. 6).
This suggests that the observed leakage caused by INF7 and
INF7-K(GalNAc)2) is likely caused by pore formation.
FIG. 4. Competition of 125I-ASOR binding to mouse parenchy-
mal liver cells by INF7 (), INF7-SGSC (), INF7-K(GalNAc)2 (f),
and K(GalNAc)2 (‚). Parenchymal liver cells (1 10
6) were incubated
for 2 h at 4 °C with 5.5 nM 125I-ASOR in the presence or absence of
0.005–5 M INF7-K(GalNAc)2. Data were analyzed according to a single
site model using a computerized nonlinear-fitting program (Prism 3.0).
The affinity of INF7-K(GalNAc)2 was calculated to be 87  16 nM
compared with 32  9 nM. Values are the means  S.D. of two deter-
minations in triplicate.
FIG. 3. Liposome leakage assay of
INF7 and JTS-1. Calcein-containing li-
posomes were incubated with 10 M pep-
tide at pH 5.0. Calcein release was quan-
tified as described under “Experimental
Procedures.” A, calcein leakage from lipo-
somes containing 2.6–40% w/w choles-
terol after incubation with INF7 (empty
bars) or JTS-1 (gray bars). B, kinetics of
JTS1- () and INF7- (f) induced calcein
leakage from 40% w/w cholesterol lipo-
somes. C, kinetics of JTS1- () and INF7-
(f) induced calcein leakage from 2.6%
w/w cholesterol liposomes. Data are the
means  S.D. of a determination in
triplicate.
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Effect of the Fusogenic Peptides on Polyplex Gene Transfer to
Mouse Parenchymal Liver Cells—Next, we assessed whether
the glycoconjugated INF7 was able to promote the release of
lysosomally entrapped DNA to the cytosol, thus enhancing the
transfection level in a receptor-dependent manner. Mouse pa-
renchymal liver cells were transfected with polyplexed DNA in
the absence or presence of fusogenic peptide. For gene transfer
we made use of the cationic peptide (K8)-based polyplex proto-
col described by Gottschalk et al. (10). Cells were transfected
with plasmid DNA (pCMVLuc), containing a CMV promoter-
driven luciferase reporter gene insert, which was condensed
with K8 (at a N:P ratio of 4:1). To exclude artifacts caused by
the presence of the SGSC linker arm between the GalNAc
cluster and the peptide, INF7-SGSC was included as a control.
Preincubation of the polyplexes with INF7 increased the trans-
fection efficiency in a dose-dependent manner up to 30-fold
(Fig. 7A). At the concentrations measured, INF-K(GalNAc)2
displayed a capacity to enhance the transfection efficiency sim-
ilar to that of INF7.
Receptor-specific Recognition of INF7-K(GalNAc)2—INF7-
K(GalNAc)2 was not able to stimulate gene transfer to BHK
cells, which do not express the ASGPr, whereas INF7 and
INF7-SGSC were found to improve the transfection efficiency
of the K8 polyplexes considerably (Fig. 7B).
To confirm that INF7-K(GalNAc)2 promoted nonviral gene
transfer of K8DNA in an ASGPr-specific fashion, the effect of
INF7-K(GalNAc)2 on the transfection efficiency was examined
in the presence of GalNAc, which blocks the ASGPr. As shown
in Fig. 7C, GalNAc did not influence the transfection ability of
polyplexes that were preincubated with INF7 or INF7-SGSC,
whereas it markedly reduced that of INF7-K(GalNAc)2-prein-
cubated polyplexes. GlcNAc, which has no affinity for the
ASGPr, by contrast, had no effect on INF7-K(GalNAc)2-stimu-
lated gene transfer. This indicates that INF7-K(GalNAc)2
exerts its fusogenic activity through the ASGPr, whereas INF7
has a more general nonspecific fusogenic effect.
Toxicity—It has been suggested that disruption of endocy-
totic and lysosomal vesicles might lead to the release of pro-
apoptotic and cytotoxic proteases. Therefore, we mapped the
toxic side effects of the targeted LDEs by evaluating the effect
of INF7 or glycoconjugated INF7, in the presence of the
K8DNA polyplexes, on the viability of parenchymal liver cells.
INF7 and INF7-K(GalNAc)2-equipped polyplexes did not show
significant toxicity in the applied relevant concentration range
(0–2 M) (data not shown).
In Vivo Behavior of INF7 and INF7-K(GalNAc)2 in Mice—To
study the biodistribution profile of INF7 and INF7-K(GalNAc)2
in mice, both peptides were iodinated and intravenously in-
jected into the vena cava of C57BL/6 mice. INF7 was cleared
rapidly from the circulation at a half-life of 2 min (Fig. 8B),
and only 5% of the injected dose could be recovered in the liver
after 30 min (Fig. 8A). Fig. 8C shows that hepatic uptake of
FIG. 5. Liposome leakage assay of
INF7 and INF7-K(GalNAc)2. Calcein
release was quantified as described under
“Experimental Procedures.” A, calcein-
laden 40% cholesterol liposomes were in-
cubated at pH 5 with 0–20 M INF7 (Œ) or
INF7-K(GalNAc)2 (f). After 30 min of in-
cubation calcein leakage was measured
and is plotted as a percent of total en-
trapped calcein. B, calcein-laden 2.6%
cholesterol liposomes were incubated at
pH 5.0 with 0–20 M INF7 (Œ) or INF7-
K(GalNAc)2 (f). C, calcein leakage from
liposomes containing 2.6–40% cholesterol
after incubation with 10 M peptide at pH
5.0. Indicated are the percentages of cal-
cein leakage from liposomes containing
various cholesterol concentrations incu-
bated with INF7 (empty bars) or INF7-
K(GalNAc)2 (solid bars). Data are the
means  S.D. of a determination in
triplicate.
FIG. 6. Liposome leakage of INF7 and INF7-K(GalNAc)2. Release of
125I-trypsin inhibitor from 2.6% cholesterol (A) or 40% cholesterol (B)
liposomes after incubation for 30 min at pH 5.0 and 7.0 in the presence of peptide (0–7.5 M). As a measure of total liposome leakage, liposomes
were incubated with 0.2% Triton X-100 (lane M). Release of liposome-incorporated 125I-trypsin inhibitor (TryI) was visualized after agarose gel
electrophoresis and subsequent autoradiography with a PhosphorImager. After quantification of the intensity of the bands no significant INF7- and
INF7-K(GalNAc)2-induced leakage was observed.
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INF7 is 5%, which was comparable with skin, bone, kidney,
and intestine. INF7-K(GalNAc)2 was cleared even more rapidly
from the circulation (half-life 2 min, Fig. 8B). In contrast to
INF7, the glycoconjugate was taken up mainly by the liver
(35–40%; Fig. 8, A and C), whereas uptake by small intestine,
kidney, and bone was significantly lower. This comparison of
the INF7 and INF7-K(GalNAc)2 biodistribution profiles indi-
cates that attachment of the K(GalNAc)2 group to INF7 specif-
ically redirects INF7 to the liver.
DISCUSSION
The main objective of this study was to improve nonviral
gene delivery by the use of targeted LDEs. As a first step we
have tested two HA-derived fusogenic peptides, JTS-1 and
INF7, for their lysosome disruptive capacity in calcein-laden
liposomes (10). INF7 was found to induce a rapid and choles-
terol-independent leakage of liposomes, whereas JTS-1-in-
duced leakage was much slower and cholesterol-dependent.
Moreover, JTS-1 was unable to disrupt cholesterol-poor (20%)
liposomes completely. These findings concur with the studies of
Gottschalk et al. (10), who showed complete leakage of choles-
terol-poor liposomes by INF7 compared with only partial leak-
age by JTS-1 (35%). The differential fusogenic profile of JTS-1
and INF7 is not the result of differences in net negative charge
or hydrophobicity of the peptides because the peptides are very
similar in that respect. Possibly, INF7 and JTS-1 have a dif-
ferent orientation in liposomal membranes (12, 37–40). Fur-
ther experiments will be imperative to confirm this hypothesis.
In the second step, the most promising peptide, INF-7, was
equipped with a homing device to render the peptide specific for
parenchymal liver cells. As a homing device we used K(Gal-
NAc)2, which was shown previously to be able to redirect lipo-
somes, lipoproteins, and drugs to liver parenchymal cells (26,
32, 41). The conjugate appeared to be slightly less fusogenic
than the parent peptide (1.3 M versus 6.1 M). However, the
lytic activity of the conjugate was cholesterol-dependent in that
it only disrupted cholesterol-poor liposomes. This may be an
advantage as K(GalNAc)2-conjugated INF7 is designed to act
specifically on the cholesterol-deficient lysosomal membranes
of ASGPr-expressing cells. INF7, by contrast, may also be
fusogenic at the level of the plasma membrane.
The intriguing observation that INF7-K(GalNAc)2-induced
leakage depends on the liposome cholesterol content, in con-
trast to INF7 alone, prompted further study. Lysosome disrup-
tive peptides may facilitate leakage, through pore formation
and through a detergent-like solubilization of the membrane
(36). The differential lytic profile of INF7 and its glycoconjugate
suggests that INF7 disrupts membranes via both pathways,
one of which predominates in cholesterol-rich membranes and
is blocked by the presence of the bulky glycoside moiety. How-
ever, the lack of leakage of 125I-trypsin inhibitor from INF7
(glycoconjugate)-treated liposomes points to pore formation as
the major pathway of liposome disruption for both INF7 and
the glycoconjugated INF7. Rather, steric hindrance of the
exposed glycoside group might interfere with the ability of the
fusogenic peptide to form pores. This also explains the reduced
lytic activity of INF7-K(GalNAc)2 in cholesterol-rich liposomes
because the liposomal cholesterol may hamper pore formation
by INF7-K(GalNAc)2 caused by steric hindrance of the glyco-
FIG. 7. Effect of INF7, INF7-SGSC, and INF7-K(GalNAc)2 on
nonviral gene transfer to mouse parenchymal liver cells (A) or
500 nM BHK cells (B). Plasmid DNA (1 g/well pCMVLuc) was con-
densed in HBS with K8 peptide at a 4:1 P:N ratio, polyplexes were
incubated in the absence (dotted bar) or presence of INF7 (empty bar),
INF7-SGSC (hatched bar), and INF7-K(GalNAc)2 (solid bar). C shows
the effect of 100 mM GalNAc and 100 mM GlcNAc on nonviral gene
transfer in the presence of (targeted) LDEs in mouse parenchymal cells.
Data are the means  S.D. of four determinations in triplicate.
FIG. 8. Liver uptake (A) and serum decay (B) of INF7 (Œ) and INF7-
K(GalNAc)2 (f) in mice. Compounds (25 g) were injected intrave-
nously, blood and liver samples were taken at indicated time points,
and radioactivity was determined. Values were plotted as percentage of
the injected dose. Liver and organ uptakes are corrected for radioactiv-
ity in entrapped serum. C, organ distribution of 125I-INF7 (empty bars)
and 125I-INF7-K(GalNAc)2 (solid bars). 30 min after the intravenous
injection of the compounds, mice were sacrificed, and organs were
excised and analyzed for associated radioactivity. Values are the
means  S.D. of two experiments.
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side group. To confirm this hypothesis, the orientation and
distribution of the peptides in the liposomal membrane need to
be addressed.
The glycoconjugated peptide was designed for ASGPr-
directed delivery. Indeed, glycoconjugated INF7 bound to the
ASGPr with an affinity of 87 nM, which is about two times lower
than K(GalNAc)2 itself. Earlier studies have shown that an
affinity of 87 nM for the ASGPr should be sufficient for effective
targeting of INF7-K(GalNAc)2 (32, 42).
The final goal of this study was to elaborate a targeted LDE
for improving nonviral gene transfer. To this end, we have
evaluated the effect of the fusogenic peptides on the gene trans-
fer efficiency of an established nonviral gene delivery protocol
based on the cationic peptide K8 in mouse parenchymal liver
cells (10). DNA polyplexed with small sized synthetic oligoca-
tions (like K8) may be better for systemic application because
the derived condensates generally are smaller and less immu-
nogenic, nonaggregating, and are readily unpacked intracellu-
larly (43, 44). INF7, INF7-SGSC, and INF7-K(GalNAc)2 led to
a substantial, 30-fold, increase in the transfection efficiency of
K8DNA complexes in freshly isolated parenchymal cells. This
stimulatory effect was concentration-dependent. Even though
in the leakage assay, INF7-K(GalNAc)2 appeared to be 6-fold
less potent than INF7, the lower intrinsic activity is compen-
sated for by the enhanced uptake of the targeted peptide, by
parenchymal liver cells. However, it should also be kept in
mind that liposomal and cellular assays are not fully
comparable.
The fusogenic activity of INF7-K(GalNAc)2 was abolished
completely in the presence of excess GalNAc, which blocks
ASGPr-mediated uptake, whereas GlcNAc had no effect on the
transfection efficiency. Moreover, INF7-K(GalNAc)2 did not
affect the transfection yield in ASGPr-deficient BHK cells,
whereas INF7 and INF7-SGSC were equally potent in BHK
and mouse parenchymal cells. This underlines that the stimu-
latory effect of glycoconjugated INF7 is mediated by the ASGPr
and will have fewer side effects. In agreement with previous
studies, primary parenchymal liver cells are more difficult to
transfect than continuous cell lines; the intrinsic transfection
efficacy in BHK cells was indeed found to be 10–100-fold higher
than in parenchymal cells (45).
The observation that INF7-K(GalNAc)2 was completely in-
active in BHK cells indicates that non-ASGPr-mediated uptake
and the lytic activity of INF7-K(GalNAc)2 are reduced consid-
erably compared with those of INF7 or INF7-SGSC. As our
leakage data already showed that the glycoconjugate is less
fusogenic, we propose that this is the major contributing factor
underlying the reduced stimulatory effect of INF7-K(GalNAc)2
in BHK cells. The actual route of entry of INF7 and INF7-
SGSC remains unclear. INF7 and INF7-SGSC may be cointer-
nalized into the target cells, associated with the polyplexes.
Because the peptides have only a very weak fusogenic activity
at pH 7.4, it is unlikely that they may be stimulatory by
facilitating polyplex/plasma membrane fusion. Cellular uptake
of the cationic polyplexes may in turn implicate the use of
receptor systems, possibly the scavenger receptor class B and
CD36 (46), or alternative pathways such as pinocytosis. INF7-
K(GalNAc)2, on the other hand, could be stimulatory by asso-
ciating with the K8DNA complex and subsequently promoting
whole complex uptake via an ASGPr-mediated pathway. Intra-
cellularly, INF7-K(GalNAc)2 will promote escape of the DNA
from the lysosomal compartment.
It has been reported that lysosome leakage and membrane
disruption may lead to intracellular release of lytic enzymes
including proteases, nucleases, and lipases. Although these
enzymes are acid hydrolases, with a catalytic optimum near pH
5.0, leakage of these enzymes in the cytoplasm of the cell could
promote apoptosis or necrosis (47). We show that the peptides
are not cytotoxic in parenchymal liver cells.
Another important issue in regard of potential in vivo use
involves the pharmacokinetics of INF7 and its glycoconjugate.
The biodistribution profile in mice shows that INF7-K(Gal-
NAc)2 is preferentially taken up by the liver, whereas INF7 is
distributed evenly over various organs. In fact, liver uptake of
the glycoconjugate is 6-fold higher than that of INF7, indicat-
ing that we have developed a hepatocyte-specific LDE for use in
vivo.
In conclusion, we present a targeted fusogenic peptide, INF7-
K(GalNAc)2, which induces lysosomal escape in a receptor-de-
pendent fashion. Its favorable pH- and cholesterol-dependent
activity profile makes it even more lysosome-specific than the
parental INF7. We envision that INF7-K(GalNAc)2 could be
applied to improve the transfection efficacy of hepatic nonviral
gene transfer vehicles (25) and of antisense drugs for hepatic
genes (42, 41, 48) by facilitating the escape from the lysosomal
pathway, which appears to be a major drawback in both ther-
apies (49). Not only gene medicines, but also other drugs that
accumulate in the lysosomal circuit might benefit from appli-
cation of targeted LDEs.
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